These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12444282)

  • 1. Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer.
    Bex A; Otto T; Lümmen G; Rübben H
    Urol Int; 2002; 69(4):273-7. PubMed ID: 12444282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate.
    Shinohara N; Demura T; Matsumura K; Toyoda K; Kashiwagi A; Nagamori S; Ohmuro H; Ohzono S; Koyanagi T
    Prostate; 1998 Apr; 35(1):56-62. PubMed ID: 9537600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
    Morant R; Bernhard J; Maibach R; Borner M; Fey MF; Thürlimann B; Jacky E; Trinkler F; Bauer J; Zulian G; Hanselmann S; Hürny C; Hering F
    Ann Oncol; 2000 Feb; 11(2):183-8. PubMed ID: 10761753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer.
    Culine S; Kramar A; Droz JP; Théodore C
    J Urol; 1999 Jan; 161(1):173-5. PubMed ID: 10037392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
    Tannock IF; Osoba D; Stockler MR; Ernst DS; Neville AJ; Moore MJ; Armitage GR; Wilson JJ; Venner PM; Coppin CM; Murphy KC
    J Clin Oncol; 1996 Jun; 14(6):1756-64. PubMed ID: 8656243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
    Droz JP; Muracciole X; Mottet N; Ould Kaci M; Vannetzel JM; Albin N; Culine S; Rodier JM; Misset JL; Mackenzie S; Cvitkovic E; Benoit G
    Ann Oncol; 2003 Aug; 14(8):1291-8. PubMed ID: 12881395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer.
    Zampino MG; Verri E; Locatelli M; Curigliano G; Ascione G; Sbanotto A; Rocca A; Verweij F; Matei V; Scardino E; Decobelli O; Goldhirsch A; Nolè F
    Anticancer Res; 2006; 26(3B):2375-80. PubMed ID: 16821619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
    Kuzel TM; Tallman MS; Shevrin D; Braud E; Kilton L; Johnson P; Kozlowski J; Vogelzang NJ; Blough R; Benson AB
    Cancer; 1993 Sep; 72(6):1965-8. PubMed ID: 8364875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
    Berlin JD; Propert KJ; Trump D; Wilding G; Hudes G; Glick J; Burch P; Keller A; Loehrer P
    Am J Clin Oncol; 1998 Apr; 21(2):171-6. PubMed ID: 9537206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U; Harstrick A; Wilke H; Seeber S
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.
    Lutz MP; Königer M; Muche R; Ellenrieder V; Steinkamp M; Adler G; Gress TM
    Z Gastroenterol; 1999 Oct; 37(10):993-7. PubMed ID: 10549093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
    de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
    J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
    J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
    Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
    Chu L; Sutton LM; Peterson BL; Havlin KA; Winer EP
    J Infus Chemother; 1996; 6(4):211-6. PubMed ID: 9229318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.